Nogo-receptors NgR1 and NgR2 do not mediate regulation of CD4 T helper responses and CNS repair in experimental autoimmune encephalomyelitis by Steinbach, K et al.
Nogo-Receptors NgR1 and NgR2 Do Not Mediate
Regulation of CD4 T Helper Responses and CNS Repair in
Experimental Autoimmune Encephalomyelitis
Karin Steinbach1, Claire L. McDonald2, Markus Reindl2, Ru¨diger Schweigreiter3, Christine Bandtlow3,
Roland Martin1*¤
1 Institute for Neuroimmunology and Clinical MS-Research, Hamburg, Germany, 2Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria,
3Department of Neurobiochemistry, Innsbruck Medical University, Innsbruck, Austria
Abstract
Myelin-associated inhibition of axonal regrowth after injury is considered one important factor that contributes to
regeneration failure in the adult central nervous system (CNS). Blocking strategies targeting this pathway have been
successfully applied in several nerve injury models, including experimental autoimmune encephalomyelitis (EAE),
suggesting myelin-associated inhibitors (MAIs) and functionally related molecules as targets to enhance regeneration in
multiple sclerosis. NgR1 and NgR2 were identified as interaction partners for the myelin proteins Nogo-A, MAG and OMgp
and are probably mediating their growth-inhibitory effects on axons, although the in vivo relevance of this pathway is
currently under debate. Recently, alternative functions of MAIs and NgRs in the regulation of immune cell migration and T
cell differentiation have been described. Whether and to what extent NgR1 and NgR2 are contributing to Nogo and MAG-
related inhibition of neuroregeneration or immunomodulation during EAE is currently unknown. Here we show that genetic
deletion of both receptors does not promote functional recovery during EAE and that NgR1 and NgR2-mediated signals
play a minor role in the development of CNS inflammation. Induction of EAE in Ngr1/2-double mutant mice resulted in
indifferent disease course and tissue damage when compared to WT controls. Further, the development of
encephalitogenic CD4+ Th1 and Th17 responses was unchanged. However, we observed a slightly increased leukocyte
infiltration into the CNS in the absence of NgR1 and NgR2, indicating that NgRs might be involved in the regulation of
immune cell migration in the CNS. Our study demonstrates the urgent need for a more detailed knowledge on the
multifunctional roles of ligands and receptors involved in CNS regeneration failure.
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Introduction
The non-regenerative nature of the adult mammalian central
nervous system (CNS) poses a major challenge to successful repair of
nerve damage occurring by either traumatic injury or during
inflammatory CNS diseases such as Multiple Sclerosis (MS). Most
likely driven by a deregulatedmyelin-specific autoreactiveCD4+Tcell
response, this disease leads to chronic inflammation, demyelination,
and neuronal and axonal degeneration [1,2]. The latter two outcomes
are considered to be the major determinants of clinical disability in
patients [3,4,5].Axonal regrowthandplasticity in theadult is limitedby
several, probably redundant regulatory pathways including inhibitory
proteins of theCNSmyelin [6], formationof a glial scar upon injury [7]
as well as lack of intrinsic growth capacity in CNS neurons [8].
Nogo receptors were identified as interaction partners for three
myelin proteins associated with the inhibition of axonal regener-
ation in the adult mammalian CNS (MAIs) – Nogo, myelin-
associated glycoprotein (MAG) and oligodendrocyte-myelin gly-
coprotein (OMgp) [9,10,11]. While NgR1 serves as common
receptor for the Nogo-66 inhibitory domain common to all three
isoforms of Nogo, Nogo-A, -B and -C, as well as MAG and OMgp;
NgR2 was shown to be binding partner for MAG [9,10,11,12].
Together with paired-immunoglobulin-like receptor B (PirB) [13]
and probably other mechanisms [14,15], signalling via NgR1,
NgR2 and coreceptors induces growth cone collapse and
inhibition of axonal regrowth as well as compensatory sprouting
of remaining axons, thereby impairing functional repair after
injury. However, although many components of this regulatory
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system have been identified by extensive and detailed studies, their
relative contribution to CNS regeneration failure in vivo is still
poorly understood.
Furthermore, alternative functions for NgR1 and NgR2 in the
regulation of nervous tissue damage recently emerged when a
potential immunoregulatory role for NgRs in inflammatory
responses was described. Although both receptors are only weakly
expressed on naive immune cells, upregulation of NgR1 and
NgR2 over time can be detected on several immune cell types after
in vitro stimulation [16], as well as in vivo in models of nerve injury
[17] and in MS lesions [18]. Upregulation of NgR1 and NgR2 was
shown to induce repulsion from myelin substrates in vitro leading to
efflux from the injured peripheral nervous system (PNS). Although
a similar function has been suggested for the CNS [19], it is so far
unknown, whether NgR1 and NgR2 regulate leukocyte migration
in the CNS in vivo.
Evidence for a disease-modifying role of MAIs in MS is
provided by studies in the established animal model, experimental
autoimmune encephalomyelitis (EAE). Blockade of Nogo leads to
an ameliorated disease course with enhanced functional recovery
associated with less permanent axonal damage [20,21,22].
Interestingly, some approaches also resulted in an altered
myelin-specific T cell response in the treated animals, supporting
an immunoregulatory role for Nogo in addition to its inhibitory
function on CNS regeneration. So far it has not been studied
whether the immunomodulatory effects of Nogo are indeed
provoked by the same receptors, e.g. NgR1, that mediate its
inhibitory functions in the CNS.
In order to understand better the potential multifunctional roles
for NgR1- and NgR2-mediated signals in the development of
inflammatory responses and the occurrence of inflammation-
induced neuronal and axonal damage and regeneration in the
CNS, we studied MOG35–55-induced chronic EAE in Ngr1
2/2
[23], Ngr22/2 and Ngr1/22/2 double mutant mice [24]. Here we
provide evidence that genetic deletion of NgR1 and NgR2 has
only minor effects on the development of inflammatory responses
in the CNS and does not improve inflammation-induced neuronal
and axonal damage in this model. However, leukocyte infiltration
was slightly enhanced in the CNS of Ngr1/22/2 double mutant
mice. Further, the lack of immunomodulatory effects in double
mutant mice indicates that the Nogo-66 receptor NgR1 is not
involved in potential immunoregulatory functions of Nogo
proteins.
Results
NgR-deficiency does not alter the clinical disease course
of EAE
In order to investigate a potential role for NgR1 and NgR2 in
the development of inflammatory responses in the CNS and/ or
recovery from the resulting neuronal and axonal damage, we
induced EAE in different NgR-deficient animals and compared
their clinical course to corresponding WT controls (Fig. 1, table 1).
Neither Ngr12/2 (Fig. 1A), Ngr22/2 (Fig. 1B) nor Ngr1/22/2 mice
(Fig. 1C) showed a significantly altered disease course compared to
corresponding WT mice, although we did observe a trend towards
slightly enhanced mean clinical scores during acute EAE at days
13–15 for Ngr22/2 and Ngr1/22/2 mice in all experiments
performed. Furthermore, there was no significant difference
between NgR-deficient mouse lines and corresponding WT
controls when analysed with respect to disease incidence, day of
disease onset or maximal disease severity (Table 1). Of note, Ngr1/
22/2 mice showed an increased mortality rate over a 50-day
observation period, which could be an additional indicator of a
Figure 1. Clinical course of EAE in Nogo receptor-deficient
animals. EAE was induced in Ngr12/2 (A), Ngr22/2 (B) and Ngr1/22/2
animals (C), and disease course was monitored in comparison to WT
controls for at least 30 days as described in materials and methods. One
representative experiment out of at least two is shown. Clinical scores
represent mean 6 s.e.m. of diseased animals (n$6; see also table 1).
doi:10.1371/journal.pone.0026341.g001
Table 1. Clinical course of EAE in Nogo receptor-deficient
animals.
WT Ngr12/2 WT Ngr22/2 WT Ngr1/22/2
Incidence 7/8 6/8 7/8 9/9 8/11 9/10
Mean day
of onsetA
11.460.3 11.760.3 11.760.9 11.060.5 10.260.3 9.860.4
Max. clinical
scoreA
3.160.2 2.560.3 3.660.1 3.860.1 3.060.1 3.360.2
Mortality rate 1/8 0/8 2/8 3/9 1/11 4/10
Disease parameters of representative experiments presented in figure 1 are
shown. Results represent mean 6 s.e.m.
A: Diseased animals only.
doi:10.1371/journal.pone.0026341.t001
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potential aggravation of acute EAE in these mice. However, since
deletion of NgR1 and NgR2 did not lead to an increased mortality
during the acute stages of EAE, we conclude that NgR1 and NgR2
apparently do not play a major role in the development of CNS
inflammation and long-term disease progression during EAE.
NgR-deficiency does not improve axonal and neuronal
loss during EAE
Based on the known functions of NgR1 and NgR2 as mediators
of myelin-associated inhibition of axonal regrowth, we hypothe-
sized that NgR-deficiency might result in enhanced repair of CNS
damage. This, however, does not necessarily have to translate into
a significant alteration of clinical symptoms during chronic EAE.
In order to determine if Ngr1/22/2 mice show enhanced recovery
at the cellular level, neuronal and axonal loss in the spinal cord of
chronic EAE mice was quantified (Fig. 2). Thirty days after EAE
induction, axonal and neuronal loss was evident in cervical spinal
cord sections in comparison to unimmunised control animals
(p,0.01 for ventral horn neuronal nuclei and axons of the dorsal
column; p,0.05 for axons of the corticospinal tract). Correspond-
ing to the similar clinical courses during chronic EAE, the loss of
ventral horn motor neurons (Fig. 2A) and axons in the dorsal
column (Fig. 2B), as well as in the corticospinal tract (Fig. 2C) was
unchanged between Ngr1/22/2 and WT mice. Thus, deletion of
NgR1 and NgR2 does not result in enhanced repair or recovery
from EAE at the cellular and functional level.
NgR-deficiency does not influence the encephalitogenic
immune response during EAE
In line with previous studies [16,17] we were able to detect
NgR1 and NgR2 mRNA expression in T cells, B cells and myeloid
cells from mouse and human origin [25]. Since the myelin-specific
immune response in MOG-immunized Nogo deletion mutants
was shown to be altered in favour of an anti-inflammatory
response associated with Th2-cytokines [20], we started to
investigate the peripheral immune response to immunisation with
MOG peptide in Ngr1/22/2 mice (Fig. 3). We observed a similar
recall response of in vitro restimulated T cells to MOG 35–55
peptide (Fig. 3A), which was not associated with a change in
production of pro- or anti-inflammatory cytokines (data not
shown). Accordingly, we detected similar frequencies of IFN-c-
producing Th1 cells, IL-17A-producing Th17 cells, IL-4-produc-
ing Th2 cells or IL-10-producing CD4+ T cells in the spleens of
Ngr1/22/2 and WT mice after immunization (Fig. 3B), indicating
that the peripheral T cell response is not substantially altered.
NgR1 has been shown to interact with B cell-activating factor
(BAFF) [26], which promotes B cell development as well as B cell
activation and differentiation into antibody-producing cells
[27,28,29]. Since the absence of NgR1 and NgR2 could result
in an enhanced availability of BAFF to B cells, we additionally
investigated the peripheral B cell response in Ngr1/22/2 mice
(Fig. 3C–D). However, anti-MOG antibody titers (Fig. 3C) as well
as the frequencies of antibody-producing cells (plasma cells,
plasma blasts and B cells; Fig. 3D) were similar in immunized
Ngr1/22/2 and WT mice.
These results indicate that the previously observed shift of the
peripheral immune response in Nogo deletion mutants [20,21] is
not due to a release from NgR1 and NgR2-mediated signals, and
that both receptors are dispensable for the priming of a peripheral
T- and B-cell response upon immunization with CFA.
NgR-deficiency does not significantly change CNS
inflammation during EAE
NgR1 and NgR2 have been implicated in the regulation of
immune cell migration into nervous tissue, particularly in the PNS
[17], and a similar function has been suggested for inflammatory
Figure 2. Neuronal and axonal damage in Ngr1/22/2mice. Neuronal and axonal loss was quantified in WT and Ngr1/22/2 animals 30 days after
EAE induction and compared to unimmunised healthy controls (HC). Cell bodies of ventral horn motor neurons were stained with anti-NeuN antibody
and neuronal nuclei were counted in cervical spinal cord sections (A). Scale bars represent 50 mm. Loss of neuronal nuclei in chronic EAE was
statistically significant (p,0.01), while differences between genotypes was not (p = 0.35; two-way ANOVA). Axons in the dorsal column (B) and
corticospinal tract (C) were stained with anti-neurofilament (NF) antibodies SMI-31 and SMI-32 and quantified as described in material and methods.
Axonal loss in chronic EAE was statistically significant (p,0.01 for DC, p,0.05 for CST), while differences between genotypes was not (p = 0.42 for DC
axons, p = 0.86 for CST axons; two-way ANOVA). Scale bars represent 20 mm. Representative staining images are shown. Results are mean 6 s.e.m..
(n$3 for HC and n= 7 for diseased animals).
doi:10.1371/journal.pone.0026341.g002
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responses in the CNS [19]. Therefore we investigated whether
NgR1 and NgR2 can influence the recruitment of inflammatory
cells to the CNS during acute EAE (Fig. 4). Since we did not
observe striking alterations in the size and distribution of acute
inflammatory lesions in the CNS of Ngr1/22/2 mice in
comparison to WT mice (Fig. 4A), we performed a detailed flow
cytometric analysis of the overall immune cell infiltration into the
CNS during acute disease (Fig. 4B–D). Although the analyzed
groups of Ngr1/22/2 and WT mice have similar mean clinical
scores (Fig. 4B), the number of CNS-infiltrating CD45+ immune
cells was slightly increased in Ngr1/22/2 mice in all three
experiments performed, although this did not reach statistical
significance (p = 0.07 in pooled data). Further, the increase in
CNS-infiltration by immune cells could not be attributed to a
single cell type, but was rather mediated by an overall increased
recruitment of different immune cells, which reached statistical
significance for T cells (p,0.01 in pooled data) (Fig. 4D). This
indicates a general influence of NgR1 and NgR2 on immune cell
migration into the CNS, although the observed effects appear
marginal and probably do not influence disease severity in Ngr1/
22/2 mice (compare Fig. 1C). Next we investigated whether this
observed slight increase in CNS-infiltration might alter the
phenotype of the inflammatory response in the CNS (Fig. 4E–J).
However, we did not observe any differences in terms of CD4+ T
cell activation (Fig. 4E), cytokine production (Fig. 4F), or in the
expression of maturation markers like MHCII (Fig. 4G), CD80
(Fig. 4H) and CD40 (Fig. 4I) on APCs like macrophages, dendritic
cell subsets and microglia. Correspondingly, we detected similar
levels of pro- and anti-inflammatory cytokines in the whole CNS
extracts (Fig. 4J), indicating that the overall inflammatory milieu in
the inflamed CNS is not changed in Ngr1/22/2 mice, even if
leukocyte migration into the CNS might be slightly facilitated.
Discussion
Strategies aiming at the improvement of axonal regeneration
and repair are currently in clinical development and are clearly
desirable for patients suffering from traumatic injury as well as
from diseases like MS, which is associated with axonal transec-
tions, neuronal loss and consequently chronic disability accumu-
lation. However, the interactions and pathways between inhibitors
of axonal regrowth like MAIs and their receptor molecules are still
poorly understood and probably far more complicated than
previously appreciated. Here we provide evidence that two
proteins involved in the negative regulation of axonal regrowth
and plasticity by MAIs, NgR1 and NgR2, are dispensable with
respect to maintaining myelin-associated inhibition of axonal
regrowth in the development and progression of autoimmune
inflammatory neurodegeneration in EAE, an established animal
model of the human disease MS.
Figure 3. Peripheral immune response in Ngr1/22/2 mice. Analysis of peripheral T cell response (A–B): Single cell suspensions from draining
lymph nodes of immunized Ngr1/22/2 or WT mice were restimulated in vitro with either MOG 35–55 peptide or anti-CD3 and resulting T cell
proliferation was assessed by 3H-thymidine incorporation (A). Cytokine production by CD4+ T cells was assessed by intracellular cytokine staining
after ex vivo restimulation with PMA/ Ionomycin. Representative staining images are shown (B). Analysis of peripheral B cell activation (C–D): Anti-
MOG antibody titres in serum were quantified at peak of disease (n$14) in comparison to healthy controls (HC, n$6) as described in material and
methods (C). Activated B cells and plasma cells were quantified by flow cytometry in splenocytes. Representative staining images are shown (D).
Results represent mean 6 s.e.m. (n$5).
doi:10.1371/journal.pone.0026341.g003
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Using several blocking strategies against Nogo-A, a potent
inhibitor of axonal regeneration, a number of studies reported
beneficial effects, which could in part be attributed to enhanced
repair mechanisms [20,21,22]. We now demonstrate that
combined genetic deletion of the Nogo-66 receptor NgR1 and
one receptor for MAG, NgR2, did not result in enhanced repair
and functional recovery from inflammation-induced axonal
damage in a chronic model of EAE. In spite of the established
role of NgR1 and NgR2 in mediating growth-inhibition of Nogo-
66 and MAG in vitro, genetic deletion of both receptors did not
result in enhanced axonal density in the corticospinal tract and
dorsal column in EAE. Since common inhibition of axonal
regrowth by Nogo-66, MAG and Omgp is at least mediated by
one additional receptor, PirB [13], and additional inhibitory cues
Figure 4. CNS inflammation in Ngr1/22/2mice at peak of disease. Representative immunohistochemical staining of CD45-positive leukocytes
in Ngr1/22/2 mice and WT controls in cervical spinal cord (upper panel) and cerebellum (lower panel) (A). Flow cytometric quantification of CNS-
infiltrating cells from Ngr1/22/2 mice and WT controls (B–D): Mean clinical scores of analysed mice (B). Numbers of CD45+ CNS-infiltrating cells
(p = 0.07, unpaired student’s t-test) (C) and different immune cell types within CD45+ cells (p,0.01 for T cells, two-way ANOVA combined with
Bonferroni post-analysis) (D). Results are pooled from three independent experiments (n$13). Flow cytometric analysis of CNS-infiltrating CD4+ T cells
(E–F). Frequencies of FoxP3+ Tregs (upper panel) and expression of activation markers CD69 and CD25 on FoxP32 effector T cells (lower panel) were
quantified. Representative staining images are shown (n= 3) (E). Cytokine production by CD4+ T cells was assessed by intracellular cytokine staining
after ex vivo restimulation with PMA/ Ionomycin. Representative staining images are shown (n= 3) (F). Flow cytometric analysis of APC (G–I). Median
fluorescence intensity of the maturation markers MHCII (G), CD80 (H) and CD40 (I) was analysed on indicated cell populations in comparison to
control stainings (n = 3). Cytokine concentration in the CNS of Ngr1/22/2 mice and WT controls during acute EAE was analyzed in whole brain
homogenates as described in material and methods (n$8) (J). Results represent mean 6 s.e.m. for all shown results.
doi:10.1371/journal.pone.0026341.g004
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probably exist, genetic deletion of NgR1 and NgR2 appears
insufficient to relieve axons from growth-inhibition by myelin and
both receptors are probably functionally compensated by PirB
and/ or other mechanisms. These data argue that the inhibition of
axonal outgrowth in the adult CNS is mediated by complex
interactions of multiple receptor-ligands and well secured to the
point that even deletion of two important receptors, NgR1 and
NgR2, does not result in enhanced axonal sprouting.
As mentioned above, there have been numerous studies
focusing on promoting axonal outgrowth in EAE by targeting
Nogo via immunisation, antibody treatment or genetic deletion.
These studies observed an influence on immune function, i.e. a
shift of the myelin-specific T cell response towards a Th2-like (anti-
inflammatory) cytokine profile, which is probably partly respon-
sible for the beneficial effects observed in these studies [20,21]. In
contrast, we did not observe alterations in T cell proliferation and
cytokine production in Ngr1/22/2 mice, indicating that Nogo is
not exerting its potential immunomodulatory functions via the
Nogo-66 receptor NgR1. Accordingly, it has been demonstrated
that human T cell proliferation and cytokine production is
insensitive to treatment with a Nogo-66-derived antagonistic
peptide [16], indicating that other receptors than NgR1 mediate
immunomodulatory functions by Nogo proteins. In fact, the Th2-
like cytokine shift observed in the above-mentioned studies might
not even be due to the blockade of Nogo-A, since a recent study
specifically targeting Nogo-A during EAE did not find differences
in the proliferative capacity, cytokine production or the ability to
transfer disease in myelin-specific T cells from treated mice
although functional repair and recovery was observed [22].
Instead, the Nogo-B isoform has been implicated in the regulation
of immune cell migration [30,31] and in the regulation of Th2-
driven inflammatory reponses in the lung [32]. Further, in contrast
to Nogo-A and Nogo-C, Nogo-B is widely expressed in immune
cells [33]. It remains to be seen whether the Nogo-B receptor
NgBR [34] or the recently identified additional common receptor
of Nogo-66, MAG and OMG, PirB, is the responsible interaction
partner for these immunoregulatory functions of Nogo-B.
During our investigation of immune cell infiltration into the CNS
during acute disease, we observed an increase in the number of
infiltrating leukocytes during the acute phase of EAE. Since this
increase was not attributable to a single cell type but affected several
investigated cells, we conclude that the absence of NgR1 and NgR2
facilitates leukocyte recruitment to the CNS in Ngr1/22/2 mice.
Leukocytes expressing NgRs are probably inhibited or even
repulsed from migrating into nervous system tissue by myelin, since
blockade or silencing of NgRs increases the adhesion of leukocytes
to myelin substrates in vitro [16,17] and the efflux of macrophages
from injured peripheral nerve tissue is associated with the
upregulation of NgR1 and NgR2 in vivo [17]. Here we provide
evidence that a similar mechanism might regulate immune cell
recruitment and/ or spreading in the CNS as has been suggested
[19]. NgR1 and NgR2 therefore probably regulate immune cell
recruitment to nervous tissue in a generalized manner.
The fact that the increase in leukocyte infiltration into the CNS is
not as pronounced as described for injured PNS and has only minor
consequences at least in the EAE model could be explained in
several ways. First, repulsion of immune cells requires the
upregulation of NgR1 and NgR2. The exact conditions of NgR
expression on immune cells infiltrating into the CNS remain to be
studied. In fact we were not able to detect upregulation of NgR1 or
NgR2 in the inflamed CNS tissue during EAE (data not shown), and
unfortunately no NgR1 or NgR2-specific antibody was available for
our study to perform flow cytometric or immunohistochemical
analysis of CNS-infiltrating cells. Additionally, upregulation of NgR
expression on immune cells or their repulsive function might be
inhibited or overruled by other signals during ongoing inflamma-
tory responses in the CNS. Last but not least, repulsion of NgR-
expressing immune cells from myelinated (healthy) CNS areas
might not be solely dependent on interactions between MAIs and
NgRs. Astrocytes, which are not present in the PNS, have a clear
role in restricting the inflammatory lesion and in the prevention of
immune cell spreading in the CNS [35]. These and other factors
could functionally compensate for the loss of NgR1 and NgR2 and
result in differences in the relative importance of NgR-mediated
regulation of immune cell migration between the CNS and the
PNS. Our data support the hypothesis that NgR1 and NgR2
regulate immune cell migration into nervous tissue. The observed
enhanced inflammatory response in Ngr1/22/2 mice demonstrates
the urgent need for further studies on the multifunctional roles of
ligands and receptors involved in the non-regenerative nature of the
adult CNS. Only with a detailed knowledge of all participants will
we be able to identify appropriate single or multiple targets in that
system, which allow a specific and safe improvement of neuronal
and axonal repair and regeneration.
Materials and Methods
Ethics statement
All animal experiments were performed in accordance with the
guidelines of the local authorities (Beho¨rde fu¨r Soziales, Familie,
Gesundheit und Verbraucherschutz Hamburg; G07/025 and
G08/007).
Mice
Wildtype C57BL6/J were obtained from the Jackson Laboratory
and bred in the animal facility of the University Medical Center
Eppendorf. Rtn4r2/2 mice (B6.129S7/SvEvBrd-Rtn4rtm1Matl) [23]
and Rtn4rl22/2 mice (B6-TgH(NgRH1)143Npa) [24] have been
previously described. These mice are further referred to as Ngr12/2
mice for Rtn4r2/2 mice, Ngr22/2 mice for Rtn4rl22/2 mice and
Ngr1/22/2 mice (for Rtn4r/Rtn4rl2 double mutant mice). For all
experiments performed, offspring of homozygote matings estab-
lished from littermate animals were used.
EAE
Six to 10 week old mice were injected subcutaneously on two
spots at the flanks with 100 ml of 200 mg MOG 35–55 emulsified
in CFA supplemented with 2 mg/ ml Mycobacterium tuberculosis
H37Ra. Immunised animals were administered 300 ng of pertussis
toxin intravenously the same day and intraperitoneally two days
later. EAE developed after approximately 10 days and was scored
daily based on a 5-point EAE scale (0: no disease symptoms; 1:
limp tail; 2: hind limb paresis; 3: partial hind limb paralysis; 3.5:
complete hind limb paralysis; 4: hind limb paralysis and fore limb
paresis; 5: moribund or dead). Food and water access for severely
disabled animals was assured. Mice with complete hind limb
paralysis continuing over 3 days or which suffered from
tetraparalysis were euthanized.
Immunohistochemistry
Mice were anesthesized and transcardially perfused with 4%
PFA. Prepared tissue was post-fixed in 4% PFA for 30 min at 4uC
and then transferred into 30% sucrose for 24 h. Cervical, thoracic
and lumbar spinal cord as well as cerebellum and forebrain were
separated, embedded in tissue freezing medium and frozen in
isopentane cooled on dry ice. Frozen tissue blocks were stored at
280uC. Cryosections of 14 or 20 mm were sliced at 217uC,
mounted onto slides and stored again at 280uC until further use.
Role of NgR1 and NgR2 in EAE
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Cryosections were incubated in blocking solution for 1 h at RT,
washed once in PBS and incubated over night at 4uC with anti-
CD45 (30-F11), anti-NeuN (A60) or anti-Neurofilaments antibod-
ies (SMI-31 and SMI-32) diluted in PBS. Sections were washed
three times in PBS for 5 min and incubated for 1 h at RT with
fluorescently labeled secondary antibodies (all from Jackson)
diluted in PBS. Nuclei were stained with H 33258. Stained
sections were washed three times in PBS for 5 min and mounted
in Fluormount G. Ventral horn motor neurons were counted in 6
ventral horns per animal in 206 epifluorescence images using
ImageJ. For quantification of axonal densities, confocal images
(636) of corticospinal tract and dorsal column were taken and
axonal densities were analysed in these regions by counting at least
500 axons per region with ImageJ.
3H-Thymidine incorporation assay
Single cell suspensions were prepared from a pool of mesenteric,
axial and brachial lymph nodes of Ngr1/22/2 animals or WT
controls eight days after immunization. Lymph node cells from
immunized animals were cultured in 96 well plates at 26105 cells/
well in RPMI supplemented with 10% FCS and 50 mM 2-
mercaptoethanol and stimulated with different concentrations of
MOG 35–55 peptide or 0.1 mg/ ml anti-CD3 (145-2C11). After
two days, cells were pulsed with 1 mCi [methyl-3H]-Thymidine
(Amersham) per well for 16 h. Cells were harvested and spotted on
filtermats using Harvester 96 MACH III M (Tomtec) according to
manufacturer’s instructions. Spotted filtermats were dried and
sealed in bags containing betaplate scintillation liquid (Perkin-
Elmer). Incorporated activity/ 96 well was assessed in a beta
counter (1450 Microbeta, Perkin-Elmer) in counts per minute
(cpm). Stimulation index of applied peptides or antibodies was
calculated by dividing the mean incorporated activity of stimulated
wells by the mean of unstimulated control wells.
Flow cytometry
Single cell suspensions of splenocytes were prepared by passing of
tissue through a 40 mm cell strainer (BD Falcon). For isolation of
CNS-infiltrating leukocytes, mice were perfused transcardially with
10 ml PBS. Brain and spinal cord were removed, minced and
digested with a solution of Collagenase/ DNaseI (Roche Applied
Science) in D-MEM for 30 min at 37uC. The digested tissue was
triturated by passage through a 40 mm cell strainer (BD Falcon).
CNS-infiltrating cells were separated from myelin debris by percoll
gradient centrifugation (30%/ 78%). Cells were recovered from the
interface. For detection of intracellular cytokines, cells were
stimulated with PMA/ Ionomycin (both Sigma-Alrich) for 5 h in
the presence of Brefeldin A (eBioscience). Flow cytometric staining
was performed in FACS-Buffer (0.5% BSA, 0.02% NaN3, PBS) in
the presence of anti-CD16/32 (Fc-Block) (93). For quantification of
CNS-infiltrating leukocytes, ten percent of the isolated cell
suspension was analyzed using TruCount tubes (BDBiosciences) in
combination with anti-CD45 staining. Fixation and permeabiliza-
tion for intracellular staining of cytokines or FoxP3 were performed
using IC fixation and permeabilization kit or FoxP3 staining buffer
set (both eBioscience) according to manufacturer’s instructions. For
intracellular cytokine staining, dead cells were excluded from the
analysis using aqua-live/dead fixable cell stain kit (Molecular
Probes). Flow cytometric analysis was performed using the following
antibodies: anti-CD3e-PacificBlue (500A2), anti-CD3e-PerCPCy5.5
(145-2C11), anti-CD4-FITC (GK1.5), anti-CD4-PacificBlue
(GK1.5), anti-CD8a-PacificBlue (53-6.7), anti-CD8a-PECy7 (53-
6.7), anti-CD11b-FITC (M1/70), anti-CD11b-PerCPCy5.5 (M1/
70), anti-CD11c-APC (N418), anti-CD11c-PECy7 (N418), anti-
CD25-APC (PC61.5), anti-CD45-APC-eFluor750 (30-F11), anti-
CD45R(B220)-PECy5.5 (RA3-6B2), anti-CD69-FITC (H1.2F3),
anti-CD80-PE (16-10A1), anti-CD138-APC (281-2), anti-FoxP3-
PE (FJK-16s), anti-IFN-c-PE (XMG1.2), anti-IL-4-PE (11B11), anti-
IL-10-APC (JES5-16E3), anti-IL-17A (eBio17B7), anti-Ly-6G-PE
(1A8), anti-Ly-6G-PacificBlue (1A8), anti-MHCII-FITC (M5/
115.15.2) and anti-NK1.1-PECy7 (PK138).
Samples were analyzed on a LSRII flow cytometer (BD) using
appropriate compensation controls and doublet discrimination.
Brain Tissue Homogenization
C57BL/6 and Ngr1/22/2 mice were sacrificed during acute
disease (13 days after immunization), brains were removed and
shock frozen in liquid nitrogen. Brains were roughly cut in half and
homogenized in modified RIPA buffer (150 mM NaCl, 50 mM
TRIS-HCl, 1% sodium deoxycholate, 1% Triton X-100, 1 mM
EDTA). Protease inhibitor cocktail (Roche, Mannheim, Germany)
and phenylmethanesulfonylfluoride (PMSF, 0.1 M in isopropanol)
were added to the lysis buffer immediately before tissue
homogenization. 1 ml lysis buffer was added per each half brain
and the tissue was homogenized on ice for 1 minute at high speed
using a T8 Ultra-turrax mixer (IKA Werke GmbH & Co. KG,
Germany). Samples were then centrifuged at 5000 rpm for
30 minutes at 4uC. Total protein concentration was determined
in the resulting supernatant with the bicinchoninic acid assay.
Samples were aliquoted and stored at 280uC.
ELISA
Serum IgG antibodies to human recombinant MOG Ig (1–125)
were analyzed by ELISA as described before [36]. Mouse sera
were diluted 1:100. Bound antibodies were detected by a HRP-
coupled anti-mouse IgG antibody (GE Healthcare Bio-Sciences,
Uppsala, Sweden).
Flow Cytomix
IL-6, IL-12p70, TGF-b1, TNF-a, IL-10, IL-17, IFN-c, IL-5,
and IL-4 concentrations were quantified in brain lysates using a
cytofluorimetry-based ELISA system (FlowCytomix, Bender
Medsystems Gmbh, Austria). In brief, brains were homogenized
in lysis buffer as described above, and stored at 280uC. Samples
were thawed on ice and cytokine concentrations were determined
according to the manufacturer’s instructions.
Statistical analysis
Two-tailed unpaired student’s t-test was used to compare the
number of CNS-infiltrating leukocytes between Ngr1/22/2 mice
and WT controls. Two-way ANOVA was used to analyse EAE
scores (repeated measures) and neuronal and axonal loss (not
repeated measures). Two-way ANOVA (repeated measures)
combined with Bonferroni post-analysis was used to analyse
different immune cell subsets between experimental groups of
Ngr1/22/2 mice and WT controls.
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